1. Hasan, A, Falkai, P, Wobrock, T, et al.; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13: 318–378.
Google Scholar | Crossref | Medline | ISI2. Samara, MT, Dold, M, Gianatsi, M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry 2016; 73: 199–210.
Google Scholar | Crossref | Medline | ISI3. Demjaha, A, Egerton, A, Murray, RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry 2014; 75: e11–e13.
Google Scholar | Crossref | Medline | ISI4. Samanaite, R, Gillespie, A, Sendt, KV, et al. Biological predictors of clozapine response: a systematic review. Front Psychiatry 2018; 9: 327.
Google Scholar | Crossref | Medline5. Nielsen, J, Nielsen, RE, Correll, CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol 2012; 32: 678–683.
Google Scholar | Crossref | Medline | ISI6. Spina, E, Avenoso, A, Facciolà, G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology 2000; 148: 83–89.
Google Scholar | Crossref | Medline | ISI7. Schulte, PF. What is an adequate trial with clozapine? Clin Pharmacokinet 2003; 42: 607–618.
Google Scholar | Crossref | Medline | ISI8. Hiemke, C, Bergemann, N, Clement, HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018; 51: 9–62.
Google Scholar | Crossref | Medline9. Howes, OD, McCutcheon, R, Agid, O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017; 174: 216–229.
Google Scholar | Crossref | Medline | ISI10. Beck, K, McCutcheon, R, Bloomfield, MA, et al. The practical management of refractory schizophrenia – the Maudsley Treatment REview and Assessment Team service approach. Acta Psychiatr Scand 2014; 130: 427–438.
Google Scholar | Crossref | Medline11. Taylor, D, Barnes, TRE, Young, AH. The Maudsley prescribing guidelines in psychiatry. 13th ed. Newark, NJ; John Wiley & Sons, 2018.
Google Scholar12. Salamone, S, Sumanth, A, Kozo, D, et al. 878 point of care testing for clozapine. Eur Neuropsychopharmacol 2019; 29: S584–S585.
Google Scholar | Crossref13. Hynes, C, Keating, D, McWilliams, S, et al. Glasgow antipsychotic side-effects scale for clozapine – development and validation of a clozapine-specific side-effects scale. Schizophr Res 2015; 168: 505–513.
Google Scholar | Crossref | Medline14. Siskind, D, McCartney, L, Goldschlager, R, et al. Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016; 209: 385–392.
Google Scholar | Crossref | Medline | ISI15. Huhn, M, Nikolakopoulou, A, Schneider-Thoma, J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394: 939–951.
Google Scholar | Crossref | Medline16. Masuda, T, Misawa, F, Takase, M, et al. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiatry 2019; 76: 1052–1062.
Google Scholar | Crossref | Medline17. Siskind, D, Siskind, V, Kisely, S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry 2017; 62: 772–777.
Google Scholar | SAGE Journals | ISI18. Shah, P, Iwata, Y, Brown, EE, et al. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. Eur Arch Psychiatry Clin Neurosci 2020; 270: 11–22.
Google Scholar | Crossref | Medline19. Taylor, DM, Smith, L, Gee, SH, et al. Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand 2012; 125: 15–24.
Google Scholar | Crossref | Medline | ISI20. Barnes, TR, Leeson, V, Paton, C, et al. Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. Ther Adv Psychopharmacol 2018; 8: 185–197.
Google Scholar | SAGE Journals | ISI21. Bartoli, F, Crocamo, C, Di Brita, C, et al. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: a meta-analysis. J Psychiatr Res 2019; 108: 24–33.
Google Scholar | Crossref | Medline22. Mouchlianitis, E, Bloomfield, MA, Law, V, et al. Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull 2016; 42: 744–752.
Google Scholar | Crossref | Medline23. Rajkumar, AP, Poonkuzhali, B, Kuruvilla, A, et al. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2013; 28: 50–56.
Google Scholar | Crossref | Medline | ISI24. Rostami-Hodjegan, A, Amin, AM, Spencer, EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004; 24: 70–78.
Google Scholar | Crossref | Medline | ISI25. Nielsen, J, Damkier, P, Lublin, H, et al. Optimizing clozapine treatment. Acta Psychiatr Scand 2011; 123: 411–422.
Google Scholar | Crossref | Medline | ISI26. Olesen, OV, Linnet, K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41: 823–832.
Google Scholar | Crossref | Medline | ISI27. Chetty, M, Murray, M. CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab 2007; 8: 307–313.
Google Scholar | Crossref | Medline | ISI28. Jerling, M, Lindström, L, Bondesson, U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368–374.
Google Scholar | Crossref | Medline | ISI29. Koponen, HJ, Leinonen, E, Lepola, U. Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 1996; 6: 69–71.
Google Scholar | Crossref | Medline30. Heeringa, M, Beurskens, R, Schouten, W, et al. Elevated plasma levels of clozapine after concomitant use of fluvoxamine. Pharm World Sci 1999; 21: 243–244.
Google Scholar | Crossref | Medline31. Bondolfi, G, Morel, F, Crettol, S, et al. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005; 27: 539–543.
Google Scholar | Crossref | Medline32. Cormac, I, Brown, A, Creasey, S, et al. A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine. Acta Psychiatr Scand 2010; 121: 393–397.
Google Scholar | Crossref | Medline | ISI33. Wetzel, H, Anghelescu, I, Szegedi, A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998; 18: 2–9.
Google Scholar | Crossref | Medline | ISI34. Raaska, K, Neuvonen, PJ. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 1998; 54: 167–170.
Google Scholar | Crossref | Medline | ISI35. Migliardi, G, D’Arrigo, C, Santoro, V, et al. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. Clin Neuropharmacol 2007; 30: 107–113.
Google Scholar | Crossref | Medline | ISI36. Olesen, OV, Linnet, K. Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 2000; 20: 35–42.
Google Scholar | Crossref | Medline37. Polcwiartek, C, Nielsen, J. The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. Psychopharmacology 2016; 233: 741–750.
Google Scholar | Crossref | Medline38. Benoit-Biancamano, MO, Adam, JP, Bernard, O, et al. A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenet Genomics 2009; 19: 945.
Google Scholar | Crossref | Medline39. Erickson-Ridout, KK, Sun, D, Lazarus, P. Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A (TA) 7TAA and UGT1A4 L48V polymorphisms. Pharmacogenet Genomics 2012; 22: 561.
Google Scholar | Crossref | Medline40. Lu, D, Xie, Q, Wu, B. N-glucuronidation catalyzed by UGT1A4 and UGT2B10 in human liver microsomes: assay optimization and substrate identification. J Pharm Biomed Anal 2017; 145: 692–703.
Google Scholar | Crossref | Medline41. Mori, A, Maruo, Y, Iwai, M, et al. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos 2005; 33: 672–675.
Google Scholar | Crossref | Medline42. Ghotbi, R, Mannheimer, B, Aklillu, E, et al. Carriers of the UGT1A4 142T> G gene variant are predisposed to reduced olanzapine exposure – an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol 2010; 66: 465–474.
Google Scholar | Crossref | Medline43. Xie, H, Wu, J, Liu, D, et al. In vitro inhibition of UGT1A3, UGT1A4 by ursolic acid and oleanolic acid and drug–drug interaction risk prediction. Xenobiotica 2017; 47: 785–792.
Google Scholar | Crossref | Medline44. Piatkov, I, Caetano, D, Assur, Y, et al. ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine. Pharmacogenomics Pers Med 2017; 10: 235.
Google Scholar | Medline45. Consoli, G, Lastella, M, Ciapparelli, A, et al. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics 2009; 10: 1267–1276.
Google Scholar | Crossref | Medline | ISI46. Naveen, M, Patil, AN, Pattanaik, S, et al. ABCB1 and DRD3 polymorphism as a response predicting biomarker and tool fo